CAPR Capricor Therapeutics Inc

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming scientific and medical conferences.

Event:	American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (Baltimore, MD)
Date:	May 7–11, 2024
Format:	Oral Presentation/Abstract: Exosome-mediated intracellular delivery of arginase-1: a potential application for the treatment of Arginase-1 Deficiency
Event:	Parent Project Muscular Dystrophy (PPMD) Cardiac Workshop III (Baltimore, MD)
Date:	May 9–10, 2024
Format:	Panel: Industry perspectives on cardiac monitoring in DMD clinical trials
Event:	International Society of Extracellular Vesicles (ISEV) 2024 Meeting (Melbourne, Australia)
Date:	May 9–12, 2024
Format:	Abstract: Targeted cargo delivery to mouse lower limb by exosomes carrying a muscle targeting moiety with intravenous injection
Event:	CureDuchenne 2024 FUTURES National Conference (Orlando, FL)
Date:	May 23–26, 2024
Format:	Presentation: CAP-1002: an allogeneic cell therapy demonstrates disease modification in later-stage DMD patients: 24-month safety and efficacy results from the HOPE-2 open label extension
Event:	International Society for Cell & Gene Therapy (ISCT) 2024 Meeting (Vancouver, Canada)
Date:	May 29–June 1, 2024
Format:	Oral Presentation/Abstract: Targeted delivery of ASO using exosomes leads to mouse dystrophin exon skipping

The posters and/or abstracts will be made available on the publications section of the Capricor website following the conclusion of the meetings.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, CAP-1002 — an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown CAP-1002 to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. CAP-1002 is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). Capricor is also harnessing the power of our exosome technology, using our proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Capricor has entered into a partnership for the exclusive commercialization and distribution of CAP-1002 for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com 858.727.1755